- Shape the Future of Your Health and Explore Your Ancestry with DNA Complete®
- World-class Whole Genome Sequencing Direct-to-Consumer test offering
- Offering deep insights for consumers, universities, and the healthcare industry with best-in-class tools and interpretation capabilities
About Us
“We believe we are destined to become a multibillion company. Our focused execution and smart diversification strategy have delivered stellar financial results, while the acquisition, licensing, and development of cutting-edge assets have billion-dollar potential. The best is yet to come.”
– Ted Karkus
ProPhase Labs is a next- generation biotech, genomics and diagnostics company focused on creating a healthier world through bold action and the power of insight. Find us on the Nasdaq, stock symbol PRPH.
We dream big and execute smartly through our diversified subsidiaries.
- The pioneers and leader in Whole Genome Sequencing with one of the most accurate, highest quality and price competitive solutions on the market.
- World class whole genome sequencing (WGS) lab in Garden City, NY with four leading platforms of WGS equipment.
- Developing groundbreaking compounds and products.
- Licensing and developing with the goal of commercializing Equivir (dietary supplement) and Equivir G (Rx), two broad based anti-virals.
- Introducing BE-Smart, a breakthrough in esophageal cancer detection.
- 30+ years of OTC manufacturing services and consumer healthcare product development from non-GMO, Organic and/or Natural-based cough drops and lozenges for over-the-counter drugs to dietary supplement products.
- Clinically-backed consumer products promoting better health, energy, and sexual vitality available online, Walmart, Walgreens, CVS, Rite-Aid and more.
We achieve extraordinary results with our focus on executional excellence, smart diversification, and a synergistic approach
Meet Our Management Team
Ted Karkus
Chairman & CEO
Ted Karkus, CEO and Chairman of ProPhase Labs, drives the company’s diverse and synergistic businesses with his successful track record in biomedical and health companies. He transformed ID Biomedical’s strategy and valuation from $25 million to $1.4 billion sale to GlaxoSmithKline. As CEO of ProPhase Labs, he restructured the go-to-market strategy for the flagship product Cold-EEZE, turned around and significantly grew revenues, ultimately selling it for $50 million to Mylan.
ProPhase Labs is a fast-growing biotech, genomics and diagnostics company due to its commitment to growth, innovation, and execution excellence outlined in Ted’s high growth roadmap. He pivoted into industry leading CLIA labs, and then further diversified by acquiring genomics leader Nebula Genomics. Constantly innovating, Ted then created ProPhase BioPharma to deliver antivirals, cancer tests and therapeutic cancer compounds. The new acquisitions and legacy businesses work to drive synergistic growth with multi-billion-dollar potential.
He holds a BS in Psychology from Tufts University with Magna Cum Laude Honors and an MBA in Finance from Columbia University School of Business with Beta Gamma Sigma Honors.
Jed Latkin
Chief Operating Officer & Head of Finance Department
Jed A. Latkin served as a director and Chief Executive Officer of Navidea from October 2018, until October 2021. Mr. Latkin has more than 28 years of experience in the financial industry supporting many investments in major markets including biotechnology and pharmaceuticals. He most recently was employed by Nagel Avenue Capital, LLC since 2010, and in that capacity he provided contracted services as a CEO/CFO for numerous healthcare related firms. Mr. Latkin worked for over ten years in Investment Banking at Citigroup, Morgan Stanley and Fleet Boston Robertson Stephens. He also spent five years as a Co-Portfolio Manager for ING Investment Management. Mr. Latkin earned a B.A from Rutgers University and a M.B.A. from Columbia Business School.
Jason Karkus
President, Nebula Genomics
Jason drove explosive revenue growth at ProPhase Diagnostics, leading multiple areas including sales, business development, logistics operations, and account management. He oversaw the development of two CLIA-certified labs, generating approximately $200 million in revenues since 2021 and manages account managers and customer service reps who offer 24/7 service to exceed customer expectations. Jason now heads up business development for the rapid build-out of ProPhase’s clinical and genomic businesses.
With a background in sales and development at top real estate firms, Jason is a graduate of the University of Maryland.
Sergio Miralles
EVP/Chief Information Officer, ProPhase, Inc.
Sergio Miralles is an experienced IT Leader with over 12 years of experience in enterprise level Cybersecurity, Infrastructure, and Architecture. Sergio is responsible for ensuring a complete end-to-end technology solution that links its lab customers’ patient data via an interface to efficiently process and report results. Previously, Sergio founded and led a successful IT consulting firm overseeing 18 IT consultants. For the last five years, his primary focus has been on the medical, lab, and diagnostics business. Sergio holds several certifications from Cisco, ISC2, and CompTIA.
Lance Bisesar
Head of Finance, corporate controller ProPhase Labs, Inc.
Lance is an accomplished finance leader experienced in all areas of finance and accounting. Lance has over 17 years of experience in working with large brands, both public and private, of varying industries and sizes.
Prior to ProPhase Labs, Lance served in finance leadership roles at multiple large brand companies including Colgate-Palmolive, Casper Sleep, Newmark and Forest Laboratories, where he was responsible for all accounting matters including financial reporting, general accounting, and related internal controls functions. He began his career with five years in public accounting with Marcum LLP. Lance earned a BBA in accounting from Hofstra University. He is a certified public accountant and is a member of the American Institute of Certified Public Accountants.